menu
    • menu

    Company profile for Glycomine

    NEW Drugs in Dev: 1
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat pho...
    Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    GlycomineUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    733 Industrial Rd, San Carlos, California 94070
    Telephone
    Telephone
    (650) 401-2016
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.glycomine.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/glycomine-inc-/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/glycominebio

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Glycomine Completes Enrollment in Ph 2b POLAR Study of GLM101
    Glycomine Completes Enrollment in Ph 2b POLAR Study of GLM101

    02 Apr 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-04-02/glycomine-completes-enrollment-in-global-phase-2b-polar-study-of-glm101-for-the-treatment-of-pmm2-cd

    PHARMIWEB
    02 Apr 2026
    Share Share
    Glycomine Starts Global Phase 2b Trial of GLM101 for PMM2-CDG
    Glycomine Starts Global Phase 2b Trial of GLM101 for PMM2-CDG

    03 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-03/glycomine-initiates-dosing-in-a-global-randomized-placebo-controlled-phase-2b-study-of-glm101-for

    PHARMAWEB
    03 Sep 2025
    Share Share
    Glycomine secures $115M for GLM101 Phase 2b trial in PMM2-CDG
    Glycomine secures $115M for GLM101 Phase 2b trial in PMM2-CDG

    16 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250416688920/en/Glycomine-Announces-%24115-Million-Series-C-Financing-to-Advance-Lead-Drug-Candidate-GLM101-into-a-Phase-2b-Clinical-Trial-for-PMM2-CDG

    BUSINESSWIRE
    16 Apr 2025
    Share Share
    Glycomine Appoints Joshua Grass as Chairperson of Board of Directors
    Glycomine Appoints Joshua Grass as Chairperson of Board of Directors

    10 Oct 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241008340338/en

    BUSINESSWIRE
    10 Oct 2024
    Share Share
    Glycomine Gets FDA Fast Track For GLM101 In PMM2-CDG
    Glycomine Gets FDA Fast Track For GLM101 In PMM2-CDG

    18 Sep 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240918280418/en

    BUSINESSWIRE
    18 Sep 2024
    Share Share
    Glycomine Announces Encouraging Efficacy Data from Phase 2 Study in PMM2-CDG
    Glycomine Announces Encouraging Efficacy Data from Phase 2 Study in PMM2-CDG

    04 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240304707699/en

    BUSINESSWIRE
    04 Mar 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search